Jens Lohr, MD from Dana-Farber Cancer Institute discusses cases when cell free DNA is most beneficial and specific patient populations and stage of disease at the 2017 American Society of Hematology.
Cases When Cell Free DNA is Most Beneficial – Specific patient populations and stage of disease
